Details of the Drug
General Information of Drug (ID: DMFZ2PI)
Drug Name |
6-bromo-5-methyl-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
6-bromo-5-methyl-1H-indole-2,3-dione; 6-BROMO-5-METHYLISATIN; 306325-13-3; 6-bromo-5-methylindoline-2,3-dione; 6-bromo-5-methyl-2,3-dihydro-1H-indole-2,3-dione; 6-bromo-5-methyl-1H-benzo[d]azolidine-2,3-dione; AC1LW5IO; CBMicro_014209; Isatin-based compound, 58; SCHEMBL5526009; AC1Q2O90; CHEMBL221830; ARONIS016716; CTK7H5981; BDBM22838; BBC/891; MolPort-001-022-207; DQZFCBOXZKQQPM-UHFFFAOYSA-N; ALBB-012856; ZX-AN011645; ZINC2052963; SMSF0004612; STK042825; SBB071631; AKOS000484014; MCULE-6005372434; FCH1317267; CB09212; KS-000049B7
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 240.05 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||